Across TCGA pan-cancer cohorts, NOL4L-DT RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of NOL4L-DT’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where NOL4L-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NOL4L-DT is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

BRCA and KIRC are the cancer types where NOL4L-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NOL4L-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	+0.053	.004	4	view →
KIRC	Female	All	−0.012	.035	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: NOL4L-DT RNA expression & survival · all NOL4L-DT data types